Neurological Outcome in Cerebrotendinous Xanthomatosis Treated With Chenodeoxycholic Acid
- 1 May 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Neuropharmacology
- Vol. 36 (3), 78-83
- https://doi.org/10.1097/wnf.0b013e318288076a
Abstract
To present the long-term neurological outcome of Jewish Israeli patients with cerebrotendinous xanthomatosis (CTX) after several years of chenodeoxycholic acid (CDCA) treatment. A cross sectional observational study of all patients with a diagnosis of CTX followed in a referral outpatient clinic during the years 2003-2012. Eighteen patients (10 men) from 11 families were enrolled. Sixteen patients were included in the analysis (2 patients had low compliance for treatment). The mean ± SD age at last evaluation was 35.0 ± 9.2 years (range, 16-45 years). After their diagnosis, at age 22.6 ± 10.8 years, all patients were treated with CDCA. Patients who started treatment after the age of 25 years had worse outcome and were significantly more limited in ambulation (P = 0.004) and more cognitively impaired (P = 0.047). Five patients who started treatment after 25 years of age continued to deteriorate despite CDCA treatment. Beginning CDCA treatment as early as possible is crucial to preventing neurological damage and deterioration in CTX. After significant neurological pathology is established, the effect of treatment is limited and deterioration may continue.Keywords
This publication has 11 references indexed in Scilit:
- Cerebrotendinous Xanthomatosis Presenting with Severe Externalized Disorder:Improvement After One Year of Treatment with Chenodeoxycholic AcidCNS Spectrums, 2010
- Chronic Diarrhea and Juvenile Cataracts: Think Cerebrotendinous Xanthomatosis and TreatPEDIATRICS, 2009
- Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological studyJournal of the Neurological Sciences, 2001
- Treatment and follow-up of children with cerebrotendinous xanthomatosisEuropean Journal of Pediatrics, 1998
- Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin.JCI Insight, 1993
- Increased Concentrations of Cholestanol and Apolipoprotein B in the Cerebrospinal Fluid of Patients with Cerebrotendinous XanthomatosisThe New England Journal of Medicine, 1987
- Long-Term Treatment of Cerebrotendinous Xanthomatosis with Chenodeoxycholic AcidThe New England Journal of Medicine, 1984
- Intensive Immunosuppression in Progressive Multiple SclerosisThe New England Journal of Medicine, 1983
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975
- Cerebrotendinous XanthomatosisArchives of Neurology, 1968